EBOS Group reports lapse of 703 performance rights

EBOS Group Limited ( (NZ:EBO) ) has provided an announcement.

EBOS Group Limited has notified the ASX of the cessation of 703 performance rights, recorded under the code EBOAA, following the lapse of conditional rights that could no longer be satisfied as of 24 April 2026. The move marginally reduces the company’s pool of outstanding equity-based incentives, signalling that certain performance or service hurdles tied to these rights were not met, though it does not materially alter the company’s overall capital structure.

The announcement, filed as an Appendix 3H on 1 May 2026, is a routine disclosure required under ASX listing rules regarding changes in issued capital. For shareholders, the lapse of these performance rights slightly limits prospective equity dilution from this particular incentive tranche, while also offering a window into the company’s incentive framework and the alignment of executive or employee rewards with performance outcomes.

The most recent analyst rating on (NZ:EBO) stock is a Buy with a N$22.92 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the NZ:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a healthcare and pharmaceutical products company listed on the ASX under the code EBO. The group typically operates across the distribution and marketing of healthcare, medical and pharmaceutical products and services to pharmacies, hospitals and other healthcare providers in Australia and New Zealand.

Average Trading Volume: 265,274

Technical Sentiment Signal: Sell

Current Market Cap: N$4.34B

For detailed information about EBO stock, go to TipRanks’ Stock Analysis page.